Cover Image

Corrigendum: Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy

Saved in:

Bibliographic Details
Main Authors:	Zhi-Ming Ding (Author), Yue Xiao (Author), Xikun Wu (Author), Haixia Zou (Author), Shurong Yang (Author), Yiyun Shen (Author), Juehua Xu (Author), Heather C. Workman (Author), Amy L. Usborne (Author), Haiqing Hua (Author)
Format:	Book
Published:	Frontiers Media S.A., 2020-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy
by: Zhi-Ming Ding, et al.
Published: (2018)

Evolving Role for Pharmacotherapy in NAFLD/NASH
by: Suzanna L. Attia, et al.
Published: (2021)

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
by: Mathias B. Møllerhøj, et al.
Published: (2022)

Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig
by: Josephine Skat-Rørdam, et al.
Published: (2021)

Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of NASH
by: David Montefusco, et al.
Published: (2022)

NAShI AVTORY
by: -
Published: (2016)

NAShI AVTORY
by: -
Published: (2015)

NAShI AVTORY
by: -
Published: (2016)

NAShI AVTORY
by: -
Published: (2015)

NAShI AVTORY
by: -
Published: (2015)

n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model
by: Marie Liebig, et al.
Published: (2019)

Unraveling Hepatic Metabolomic Profiles and Morphological Outcomes in a Hybrid Model of NASH in Different Mouse Strains
by: Gabriel P. Bacil, et al.
Published: (2023)

NASH E OS PASTEIS
by: Alexandre Godinho Bertoncello, et al.
Published: (2016)

NASH E OS PASTEIS
by: Alexandre Godinho Bertoncello, et al.
Published: (2016)

Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients
by: Thomas Monfeuga, et al.
Published: (2024)

Genetics, pharmacotherapy, and dietary interventions in childhood obesity
by: Joe Eun Son
Published: (2024)

NASH and Systemic Complications From Basic to Clinical Research
Published: (2022)

Imaging biomarkers of NAFLD, NASH, and fibrosis
by: Veeral Ajmera, et al.
Published: (2021)

Bofutsushosan (Fangfengtongshengsan) improves early stages of NASH via the gut-liver axis in diabetes-induced NASH model mice
by: Mitsue Nishiyama, et al.
Published: (2024)

Dietary Intervention Accelerates NASH Resolution Depending on Inflammatory Status with Minor Additive Effects on Hepatic Injury by Vitamin E Supplementation
by: Julie Hviid Klaebel, et al.
Published: (2020)

The Choise of Valentines; Or the Merie Ballad of Nash His Dildo
by: Nash, Thomas, 1567-1601; Farmer, John Stephen, 1854-1916 [Editor]

The emergence of NASH issues after cure of hepatitis C
by: Lawrence Serfaty
Published: (2018)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
by: Brian Finan, et al.
Published: (2021)

FGF19 and FGF21: In NASH we trust
by: Saswata Talukdar, et al.
Published: (2021)

Corrigendum to "Australian Pregnant Women's Awareness of Gestational Weight Gain and Dietary Guidelines: Opportunity for Action"
by: Khlood Bookari, et al.
Published: (2017)

Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
by: Huisman TM, et al.
Published: (2021)

Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH
by: Gavin Fredrickson, et al.
Published: (2021)

Interdisciplinary advances reshape the delivery tools for effective NASH treatment
by: Linshan Chen, et al.
Published: (2023)

Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus
by: W. K. Karcz, et al.
Published: (2011)

Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non‐alcoholic steatohepatitis (NASH)
by: Natsuko Hada, et al.
Published: (2023)

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
by: Gaoxuan Shao, et al.
Published: (2022)

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
by: Shuja SH, et al.
Published: (2021)

Liver ultrasound scanning in the detection of hepatic steatosis and fibrosis in NASH patients
by: Mona Hegazy, et al.
Published: (2012)

Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach
by: Paola Orlandi, et al.
Published: (2021)

Dietary Intake and Asthma in Preschoolers: A Logistic Lasso Regression Analysis
by: Yangming Qu, et al.
Published: (2022)

Corrigendum: Effect of chlorogenic acid supplementation in MPTP-intoxicated mouse
by: Saumitra S. Singh, et al.
Published: (2023)

Marvel Carbureter and Heat Control As Used on Series 691 Nash Sixes Booklet S
by: Anonymous

Salidroside may target PPARα to exert preventive and therapeutic activities on NASH
by: Xueru Chu, et al.
Published: (2024)

Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi
by: Xuelian Xiong, et al.
Published: (2019)

Corrigendum to "Mouse Mesenchymal Progenitor Cells Expressing Adipogenic and Osteogenic Transcription Factors Suppress the Macrophage Inflammatory Response"
by: Natalie Fernandez, et al.
Published: (2019)